Background: Digital nuclear morphometric analysis can capture subtle differences along neoplastic progression. Studies showed different profiles from normal to cancer lesions. Our goal is to utilize this method as biomarker in chemoprevention trials.
Methods: Postmenopausal women were randomized to oral (CEE) or transdermal (E2) estrogen replacement therapy (ERT) in association with fenretinide or placebo. Ultrasound-guided fine needle aspiration (FNA) was performed at baseline and after 12 months in a subset of subjects.
Results: Ten samples were analyzed by karyometry. E2 compared with CEE increased nuclear area (p=0.01). A similar pattern was observed for other DNA content and chromatin texture features. Fenretinide vs. placebo, increased nuclear area and shape while decreased slope, peak and entropy.
Conclusion: Preliminary results indicate that nuclear morphometry is feasible on FNA samples. ERT and fenretinide induced significant karyometric changes. These results support further investigation of this procedure as surrogate biomarker in chemoprevention trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.breast.2007.07.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Value of Levels in Premenopausal Women at Risk of Breast Cancer-Evidence from a 17-Year Follow-Up Study.
Cancers (Basel)
April 2024
Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Article Synopsis
- The study investigates the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cholesterol regulation as a potential biomarker for breast cancer risk in premenopausal women.
- A cohort of 235 women was followed for 17 years within a clinical trial comparing tamoxifen, fenretinide, and placebo, while measuring plasma levels of PCSK9 and their associations with breast cancer events.
- Results showed no significant correlation between high PCSK9 levels and breast cancer risk, but identified a negative correlation between PCSK9 and estradiol levels, alongside various cholesterol metrics.
Fenretinide in Young Women at Genetic or Familial Risk of Breast Cancer: A Placebo-Controlled Biomarker Trial.
Cancer Prev Res (Phila)
June 2024
Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Unlabelled: Fenretinide, a retinoid with a low-toxicity profile that accumulates in the breast, has been shown to prevent second breast cancer in young women. Fenretinide exhibits apoptotic and antiinvasive properties and it improves insulin sensitivity in overweight premenopausal women with insulin resistance. This study aimed to further characterize its role in cancer prevention by measuring circulating biomarkers related to insulin sensitivity and breast cancer risk.
View Article and Find Full Text PDFVisual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
Cochrane Database Syst Rev
December 2020
Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK.
Background: Age-related macular degeneration (AMD) is a highly prevalent condition in an ever-increasing elderly population. Although insidious in the early stages, advanced AMD (neovascular and atrophic forms) can cause significant visual disability and economic burden on health systems worldwide. The most common form, geographic atrophy, has no effective treatment to date, whereas neovascular AMD can be treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections.
View Article and Find Full Text PDFOral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.
Cochrane Database Syst Rev
September 2019
Department of Pediatrics, Montreal Children's Hospital, 2300 Tupper Street, Montreal, QC, Canada, H3H 1PA.
Background: Progressive lung damage causes most deaths in cystic fibrosis. Non-steroidal anti-inflammatory drugs (such as ibuprofen) may prevent progressive pulmonary deterioration and morbidity in cystic fibrosis. This is an update of a previously published review.
View Article and Find Full Text PDFQuality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women.
Cancer Prev Res (Phila)
December 2018
Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom.
Menopausal symptoms are the main reason for withdrawal in tamoxifen prevention trials. Here, we present Menopause Quality of Life (MenQoL) assessment within a randomized 2 × 2 phase II clinical trial of low-dose tamoxifen and the synthetic retinoid fenretinide. A total of 235 premenopausal women at higher risk for breast cancer were randomized to either tamoxifen 5 mg daily, fenretinide 200 mg daily, their combination, or placebo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!